Why It Matters

Spyre Therapeutics Inc. is entering federal lobbying for the first time, marking a strategic shift as the clinical-stage biotech advances inflammatory bowel disease treatments. By hiring Arnold & Porter Kaye Scholer LLP—representing over 140 clients with $41 million in lobbying compensation—Spyre gains immediate credibility in healthcare policy.

The company’s focus on "FDA policies relating to monoclonal antibody products" positions it to influence regulatory pathways during a pivotal moment in drug development policy. Key areas include:

Lead lobbyist Robert Michael McMillin served as General Counsel for the Senate HELP Committee—the primary FDA oversight committee—providing direct institutional knowledge of congressional drug approval processes.

By the Numbers

Spyre Therapeutics Inc. registered its first lobbying engagement on March 6, 2025, retaining Arnold & Porter Kaye Scholer LLP to focus on FDA policies relating to monoclonal antibody products.

Lobbying Team: Robert Michael McMillin is the sole registered lobbyist. McMillin brings substantial healthcare experience, having represented Exelixis Inc., Bluebird Bio Inc., Novo Nordisk Inc., and others. He served approximately five years in the U.S. Senate, including as General Counsel for the Senate HELP Committee.

The Competitive Landscape

Genmab US Inc. spent $240,000 lobbying on monoclonal antibody guidance from late 2024 through Q3 2025. Lilly USA LLC has filed quarterly reports addressing monoclonal antibody coverage decisions and pricing issues.

The Agenda

Spyre Therapeutics Inc. is lobbying broadly on "FDA policies relating to monoclonal antibody products" without specific legislative targets yet. The clinical-stage biotech developing monoclonal antibodies for inflammatory bowel disease aims to influence regulatory pathways as its pipeline advances.

The company’s focus aligns with active congressional modernization efforts. The bipartisan Scientific EXPERT Act would create formal FDA meetings with medical experts and drug sponsors, potentially streamlining approval for complex biologics. The FDA recently announced it will phase out mandatory animal testing for monoclonal antibodies, accepting AI models and organoids instead.

Congressional awareness of IBD patients is growing. Rep. Eleanor Holmes Norton introduced legislation requiring retail restroom access for individuals with Crohn’s disease and ulcerative colitis—the exact population Spyre targets.

Between The Lines

Congress is actively shaping the regulatory environment as Spyre begins lobbying. The Scientific EXPERT Act of 2025, sponsored by Reps. Doris Matsui (D-CA) and Gus Bilirakis (R-FL) and Sens. Amy Klobuchar (D-MN) and Roger Wicker (R-MS), modernizes drug development by creating structured meetings between FDA, medical experts, drug sponsors, and patient organizations.

Rep. Buddy Carter (R-GA) praised domestic antibody manufacturing expansion, reflecting congressional interest in strengthening pharmaceutical supply chains. Recent hearings examined biosimilar market health and HHS budget priorities for FDA operations, focusing on accelerating approval processes.

The Bottom Line

Spyre Therapeutics has entered federal lobbying at a moment of significant regulatory modernization. Spyre joins competitors like Genmab and Lilly in shaping monoclonal antibody regulations, timing its entry with bipartisan congressional momentum on the Scientific EXPERT Act. For a smaller biotech, this represents a calculated bet that insider access and policy influence will matter as its IBD treatments advance toward regulatory scrutiny.

For more detailed insights access Legis1. Request a demo today!

Spot something wrong? Report an issue with this article